Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.52−0.11 (-6.75%)
Close on Nov 17, 2026Market cap $93.66MP/E –Yield –
Voyager Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Voyager Therapeutics's price to book ratio was 0.7× on Nov 11, 2026, against 1.0× a year earlier. Over the last 5 years it ranged from 0.6× to 5.0×, with a median of 1.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.7× | −0.3 |
| 2025 | Dec 31, 2025 | 1.0× | +0.1 |
| 2024 | Dec 31, 2024 | 0.9× | −1.2 |
| 2023 | Dec 29, 2023 | 2.1× | −0.8 |
| 2022 | Dec 30, 2022 | 2.9× | +1.8 |
| 2021 | Dec 31, 2021 | 1.2× | −0.4 |
| 2020 | Dec 31, 2020 | 1.6× | −3.1 |
| 2019 | Dec 31, 2019 | 4.8× | +0.1 |
| 2018 | Dec 31, 2018 | 4.6× | −0.5 |
| 2017 | Dec 29, 2017 | 5.1× | +2.9 |
| 2016 | Dec 30, 2016 | 2.2× | – |
See a number that looks wrong?